Original Articles. Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests?
|
|
- Bertina Jennings
- 5 years ago
- Views:
Transcription
1 Original Articles Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests? Siavash Azadmanesh Samimi, MD; Roxanne R. Mody, MD; Steven Goodman, MD; Eric Luna, BS; Donna Armylagos, BS; Mary R. Schwartz, MD; Dina R. Mody, MD; Yimin Ge, MD Context. Persistent infection with high-risk human papillomavirus (hrhpv) is the major cause of cervical cancer. The effect of HPV infection patterns on cytologic detection of cervical lesions is unknown. Objective. To determine the effect of HPV infection patterns on the sensitivity of cytologic detection of highgrade cervical lesions. Design. Papanicolaou tests from 257 women with biopsy-confirmed, high-grade squamous intraepithelial lesions were analyzed with respect to HPV infection patterns. Results. Among 257 biopsy-confirmed, high-grade squamous intraepithelial lesion cases, the preceding cytology showed 20 cases (8%) were benign; 166 cases (65%) were low-grade cervical lesions, including atypical squamous cell of undetermined significance and lowgrade squamous intraepithelial lesions; and 71 cases (28%) were high-grade cervical lesions, including atypical squamous cells cannot rule out high-grade squamous intraepithelial lesion (atypical squamous cell high), atypical glandular cells, and high-grade squamous intraepithelial lesions. In 236 cases tested for HPV, those exhibiting low-grade cervical lesions on cytology were often associated with coinfections of mixed hrhpv genotypes (31 of 40; 78%) or non-16/18 hrhpv (75/103; 73%), compared with single-genotype infections of HPV-16 (33 of 62; 53%) or HPV-18 (2 of 6; 33%) (P ¼.001). In contrast, highgrade cervical lesion cytomorphology tended to associate with the single-genotype infection of HPV-16 (20 of 62; 32%) or HPV-18 (3 of 6; 50%), compared with non-16/18 hrhpv (25 of 103; 24%) or multigenotype infection (8 of 40; 20%) (P ¼.01). Conclusions. Our findings suggest that multigenotypic or non-16/18 hrhpv infections often produce deceptive lower-grade cytomorphology, which could result in underdiagnosis and delay of treatment. The HPV infection patterns may offer unrecognized benefit beyond HPV genotyping and should be considered during clinical risk evaluation of women with lower-grade cytology. (Arch Pathol Lab Med. 2018;142: ; doi: / arpa oa) More than 40 genotypes of human papillomavirus (HPV) are known to infect the anogenital region. The genital HPV types are categorized according to their oncogenic potential. 1 The HPV genotypes 16 (HPV-16) and 18 (HPV- 18) potentiate approximately 70% of cervical cancer cases. 2 Accepted for publication May 24, Published as an Early Online Release November 21, From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Drs Azadmanesh Samimi, D. Mody, Goodman, Schwartz, and Ge; Mr Luna; and Ms Armylagos); the School of Medicine, University of Texas Health Science Center, Houston (Dr R. Mody); the BioReference Laboratories, Houston (Mr Luna and Ms Armylagos); and the Department of Pathology and Genomic Medicine, Weill Medical College of Cornell University, New York, New York (Dr Ge). The authors have no relevant financial interest in the products or companies described in this article. Presented in part at the annual meeting of the United States and Canadian Academy of Pathology; March 16, 2016; Seattle, Washington. Reprints: Yimin Ge, MD, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, 6565 Fannin St, Suite M227, Houston, TX ( yge@houstonmethodist.org). Persistent infection with oncogenic high-risk HPV (hrhpv) genotypes is the major cause of cervical cancers and precancerous lesions. 3 Studies have demonstrated that more than 85% of women with cervical cancer precursors had detectable hrhpv DNA. 4,5 In one study, the risk of developing high-grade squamous intraepithelial lesions (HSILs) was 17% and 14% for women infected with HPV- 16 and HPV-18 genotypes, respectively. In comparison, the incidence was 3% among women with positive results for other types of hrhpv. 5 The most recent consensus guidelines for screening cervical cancer recommend that women older than 30 years undergo Papanicolaou (Pap) and hrhpv testing (cotesting) every 5 years (preferred) or Pap testing only every 3 years (accepted). 6 In a previous study, the sensitivity of a single Pap test was between 60% and 80%, and the false-negative rate of 3 consecutively negative Pap test results was approximately 6%. 7 For women older than 30 years, cotesting lowered the rate of false-negative results. 8,9 The management strategy for a small group of women who have positive hrhpv and negative Pap test results is under debate. The most recent American Society of Colposcopy and Cervical Pathology management guidelines (2012) 10 Arch Pathol Lab Med Vol 142, March 2018 HPV Infections and High-Grade Lesions Samimi et al 347
2 Figure 1. Cytology diagnoses of preceding Papanicolaou tests in women with high-grade squamous intraepithelial lesions (HSILs) on follow-up biopsy: negative results for intraepithelial lesions or malignancy (NILM; 20 of 257; 8%), atypical squamous cell of undetermined significance (ASC-US; 71 of 257; 28%), atypical squamous cell, cannot rule out HSILs (ASC-H; 31 of 257; 12%), low-grade squamous intraepithelial lesion (LSIL; 95 of 257; 37%), HSIL (34 of 257; 13%), and atypical glandular cells (AGC; 6 of 257; 2%). suggested an earlier colposcopic examination for the small population of women with negative Pap test and positive HPV-16 or HPV-18 results. The effect of HPV genotype-specific infection patterns on the rate of cytologic detection of significant cervical lesions is unclear. Recent data suggest that coinfection with multiple strands of HPV potentially alters their oncogenic effect in comparison to single-genotype infection. 11 Infection with multiple genotypes of HPV reportedly occurs in 5% to 30% of infected women. 12 The current study aimed to determine the association between the genotype-specific patterns of HPV infection and the sensitivity of the Pap test in women with biopsy-confirmed HSIL. DESIGN The Pap tests recorded in our laboratory information system between March 2013 and June 2014 were analyzed along with results from hrhpv testing (Cobas 4800 system, Roche Molecular Diagnostics, Pleasanton, California) and follow-up biopsies, when available. The cervical lesions detected on Pap tests were categorized into 2 general groups: low-grade cervical lesions, encompassing atypical squamous cells of undetermined significance (ASC-US) and low-grade squamous intraepithelial lesions (LSILs), and high-grade cervical lesions (HGCLs), including ASC, cannot rule out HSILs; atypical glandular cells; HSILs, and carcinomas. The results of follow-up biopsies, performed within 14 months of cytology-hpv cotesting, were recorded. Cervical intraepithelial neoplasia grade 2 or worse on biopsy were considered HSILs. All cervical intraepithelial neoplasia grade 2 lesions were confirmed by immunohistochemical staining for p16 and Ki-67. Real-time histologic-cytologic correlation was performed at the time of biopsy sign-out, as per our usual clinical practice. All Pap tests were performed with 1 of the 2 liquid-based methods, in accordance with the preference of the referring practitioner: ThinPrep (Hologic, Madison, Wisconsin) and SurePath (Becton Dickinson, Franklin Lakes, New Jersey). Of the 257 cases with biopsy-confirmed HSIL, the preceding Pap tests were performed on the ThinPrep platform in 133 cases (51.8%) and on the SurePath platform in 124 cases (48.2%). The indication for cervical biopsy was not solely based on the preceding Pap test results. Some patients were referred to colposcopy based on their HPV genotyping results or other clinical situations. The cytologic data acquired by our laboratory were benchmarked with the College of American Pathologists Laboratory Accreditation Program database. The Pap tests and biopsies were interpreted by board-certified cytopathologists or gynecologic pathologists in an academic medical center. RESULTS In this general screening population, the HSIL reporting rate on cytology was 0.24% (313 of cases), and there was consistent cytohistologic correlation in 70% (167 of 239) of the cases. Most cases with uncorrelated data were due to tissue-sampling variances (98%; 234 of 239 cases). A total of 257 women had HSIL on follow-up biopsies, with an average age of 37.9 years (range, years). Of the women with biopsy-confirmed HSIL, the preceding Pap test diagnoses included 20 negative results (8%) for intraepithelial lesions or malignancy; 71 cases (28%) of ASC-US; 31 (12%) ASCs, cannot rule out HSILs; 6 (2%) atypical glandular cells; 95 (37%) LSIL; and 34 (13%) HSILs (Figure 1). No carcinomas or other malignancies were identified in the group. Seventy-one cases (28%) had high-grade cytologic lesion (HGCL) index Pap test results, including ASC, cannot rule out HSILs; atypical glandular cells; and HSILs. Cobas HPV cotesting was performed in 236 of the 257 biopsy-confirmed HSIL cases (92%). Of those, hrhpv was detected in 92% (n ¼ 215) of the cases, and results were negative in 9% (n ¼ 21) of the women. The biopsies that tested positive for hrhpv showed 4 unique infection patterns: (1) single-genotype HPV-16 (62 of 215; 29%) or (2) HPV 18 (6 of 215; 3%) infections, (3) non-16/18 hrhpv infections (107 of 215; 50%), and (4) mixed infection patterns with combined HPV-16, HPV-18, and/or non-16/ 18 hrhpv (40 of 215; 19%) genotypes (Figure 2). The Pap test results with the corresponding hrhpv genotypes detected on cotesting are provided in the Table. Cytologically, low-grade cervical lesions were often associated with 2 HPV infection patterns: (1) mixed genotype (31 of 40; 77%) and non-16/18 hrhpv infection (75 of 103; 73%). However, the lower-grade cytomorphology was significantly less common in single-hpv genotype infections of HPV-16 (33 of 62; 53%) or HPV-18 (2 of 6, 33%) (P ¼.01). In contrast, HGCLs on Pap test were more often associated with single-genotype infection of HPV-18 (3 of 6; 50%) or HPV-16 (20 of 62; 32%), compared with non-16/18 hrhpv genotypes (25 of 103; 24%) or mixed infection pattern (8 of 40; 20%) (P ¼.01) (Figure 3). Among 21 women with HSIL on biopsy who tested negative for hrhpv, 19 (90%) had abnormal Pap tests, including 12 cases (57%) of HGCL and 7 cases (33%) of low-grade cervical 348 Arch Pathol Lab Med Vol 142, March 2018 HPV Infections and High-Grade Lesions Samimi et al
3 Figure 2. Infection pattern of high-risk human papilloma virus (hrhpv) in women with high-grade squamous intraepithelial lesions (HSIL) on follow-up biopsy: negative for hrhpv (21 of 215; 9% [not shown]), single-genotype HPV-16 (62 of 215; 29%), HPV-18 (6 of 215; 3%), non-16/18 hrhpv (107 of 215; 50%), and mixed pattern with combined HPV-16/18 and/or non-16/18 hrhpv (40 of 215; 19%). Percents shown in the figure exceed 100% due to rounding. lesion. Only 2 women (10%) with biopsy-confirmed HSIL had double-negative results on the preceding HPV-cytology cotesting (Table). DISCUSSION Persistent infection with hrhpv causes most cervical cancers and precancerous lesions. 3 In recent years, the Cobas hrhpv test with HPV-16/18 genotyping has been increasingly used in clinical practice as an additional test, along with the Pap test, for cervical cancer screening and triaging patients with ASC-US. The effect of HPV infection patterns on cytomorphology and detection of HGCL by the Pap test is unknown. In this study, we analyzed the association of hrhpv infection patterns with cytologic diagnoses in women with biopsy-proven HSIL. In this cohort of biopsy-confirmed HSIL, the patients were stratified into 5 groups according to the HPV test results: (1) HPV-16, (2) HPV-18, (3) non-16/18 hrhpv, (4) mixed hrhpv, and (5) negative for hrhpv. We found that the lower-grade cytomorphology (ASC-US and LSIL) was significantly associated with HPV infections of non-16/18 hrhpv and mixed hrhpv infection patterns. In contrast, single-genotype infections of HPV-16 or HPV-18 were more frequently associated with high-grade cytomorphology on Pap tests (Figure 4, A through D). Our findings suggest that non-16/18 or mixed hrhpv infections tend to produce predominantly lower-grade cytomorphology than singlegenotypic infections of HPV-16 or HPV-18 do, which may result in underdiagnosis of Pap test results and delay of clinical follow-up or necessary intervention. According to the ATHENA trial (A Trial With Dronedarone to Prevent Hospitalization or Death in Patients with Fibrillation), 12.5% of women older than 21 years had an hrhpv infection other than the HPV-16/18 genotypes. 13 In our cohort of women with biopsy-confirmed HSIL, 45% were infected with non-16/18 hrhpv and 17% with mixedhrhpv genotypes. Given that these women were more likely to have lower-grade lesions on their Pap tests, cotesting with HPV testing and genotyping likely helped reduce underdiagnosis and delay of treatment. In our previous study on women diagnosed with LSIL on cytology, those with infection of a non-16/18 hrhpv genotype were more likely to have persistent disease or to progress to HGCL. 14 This suggests that these women with LSIL cytology and non-16/18 HPV infection tended to harbor high-grade lesions and were more likely to be underdiagnosed because of deceptive lower-grade cytomorphology. According to the American Society for Colposcopy and Cervical Pathology 2012 guidelines, 10 a second colposcopic examination can be delayed by 1 to 3 years after a diagnosis of LSIL or ASC-US from Pap tests with negative HPV-16/18 results. In view of our data, a reduced threshold for colposcopy or other intervention may be considered for women infected with non-16/18 hrhpv or mixed-hrhpv genotypes. Women infected with these genotypes may harbor HGCL despite deceptive lower-grade cytomorphology. Because HPV vaccination is gradually taking effect in the North American population, the predominant HPV infection patterns are expected to change. The HPV-16 and HPV-18 genotypes may be less likely to occur over time as the predominant single-genotype infectious pattern, whereas non-16/18 hrhpv and possibly other uncommon genotypes become more prominent. 1 In addition, the significant increase in human migration around the world in recent decades has caused a dramatic change in genotypic composition of HPV in North American populations. 2,15 The shifting of HPV genotypic prevalence will have significant effect on current screening practices because infections of non-16/18 hrhpv and mixed-hpv genotypes often produce Association of Human Papillomavirus (HPV) Infection Patterns and Cytology Diagnoses in Women With Biopsy-Confirmed, High-Grade Squamous Intraepithelial Lesions hrhpv Test NILM, No. (%) LGCL, No. (%) HGCL, No. (%) Total (N ¼ 215), No. HPV-16 9 (14) 33 (53) 20 (32) 62 HPV-18 1 (16) 2 (33) 3 (50) 6 Non-16/18 hrhpv 7 (6) 75 (70) 25 (23) 107 Mixed hrhpv 1 (2) 31 (77) 8 (20) 40 Abbreviations: HGCL, high-grade cervical lesions, encompassing atypical squamous cell, cannot rule out high-grade squamous intraepithelial lesion, atypical glandular cells, and high-grade squamous intraepithelial lesion; hr, high-risk; LGCL, lower-grade cervical lesions, encompassing lowgrade squamous intraepithelial lesion and atypical squamous cells of undetermined significance; NILM, negative for intraepithelial lesions or malignancies. Arch Pathol Lab Med Vol 142, March 2018 HPV Infections and High-Grade Lesions Samimi et al 349
4 Figure 3. Association of human papilloma virus (HPV) infection patterns with cytologic detection of low-grade cytologic lesion (LGCL) and high-grade cytologic lesions (HGCL) in women with biopsy-confirmed, high-grade squamous intraepithelial lesions. Infections with mixed HPV and non-16/18 high-risk (hr)hpv genotypes often produced lower-grade cytomorphology compared with single-genotype HPV infection of HPV-16 or HPV-18, which often caused high-grade cytologic changes. deceptive lower-grade cytomorphology. Further studies are needed to establish sensitive and effective screening approaches to adapt to the growing challenge of genotypic shifting of HPV in North American populations. The mechanisms of deceptively lower-grade cytomorphology observed in women infected with non-16/18 hrhpv and mixed-hrhpv genotypes are unknown. In previous studies, multigenotype HPV infections were documented in 20% to 30% of women with HGCLs In our study cohort, at least 17% of the patients with biopsyproven HSIL demonstrated coinfection with 2 or more HPV genotypes. The actual percentage of multigenotype HPV infections in this cohort could be much higher because 45% of the women were infected with non-16/18 hrhpv, which could represent single or multiple genotypes in a battery of the remaining 12 hrhpv types. A host of different immunomodulatory mechanisms has been suggested for the lower-grade lesions in multigenotype HPV infections. 19 Recent studies suggest viral antagonistic interaction among a number of HPV genotypes. 20 This result was based on observations that patients who are seropositive for multiple HPV types have a lower risk of developing cervical cancer. 21 The mechanism of intergenotypic competition is complex and depends on all stages of infection, from binding sites/ receptors to genomic expression within host cells and interaction with the immune system of the host. Further studies are needed to unravel the underlying mechanism. The Cobas platform detects 14 hrhpv genotypes, including HPV-16 and HPV-18, in addition to HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-66, and HPV-68, commonly referred to as non-16/18 hrhpv types. 22 The sensitivity and specificity of the Cobas HPV for detecting hrhpvs were 91.7% and 97.0%, respectively. 23 A previous study 9 showed 21 of 236 biopsy-proven HSIL cases (9%) with no detectable HPV on the Cobas platform. This could be due to infection with rare HPV genotypes, which are not covered by the testing panel of the Cobas platform. Other potential contributing factors include sampling variation, low viral loads, technical errors, truly non-hpv driven lesions, as well as false-negative results because of interference from reagents. 9 This finding raises a question about the effectiveness of the Cobas HPV testing as a primary-screening method for high-grade cervicovaginal lesions. Our data clearly demonstrated that the false-negative rate was greatly reduced by combining cytology and HPV testing, thus providing further support for cytology-hpv cotesting as the best current strategy for detection of high-grade cervicovaginal lesions. Despite the observed trends in this study, our results should be interpreted cautiously because most of the biopsies were performed within 1 year of the Pap tests, which is shorter than the 3-year window recommended by the US Preventive Services Task Force. This limits the ability to observe the effects of delayed diagnosis because of the false-negatives on screening and the corresponding followup results. In this small cohort, the HSIL correlation rate between cytology and biopsy was misleadingly low because the study group did not include women with Pap test results alone or those with HSIL on a Pap test but who had the biopsy performed elsewhere. On the other hand, some women were referred to colposcopy because of positive HPV test results, regardless of their Pap test results, which may also be a contributing factor. In addition, this is a retrospective, cross-sectional study, and follow-up data regarding the long-term effect of cytologic changes in patients with single versus multiple genotype infections of HPV are not available for assessment. The focus of this study was to investigate the association of cytomorphologic changes with the pattern of HPV genotype infection, regardless of immunomodulatory factors, such as tobacco use, HIV status, sexual history, and prior history of cervical intraepithelial lesions. Our study had a relatively small cohort of biopsy-proven HSIL cases, a fact which limited our interpretation of the less-frequent HPV genotypes. Given the limited genotyping panel of the Cobas 4800, we were unable to further analyze the interaction among various HPV genotypes, in the group with multigenotype HPV infection. 350 Arch Pathol Lab Med Vol 142, March 2018 HPV Infections and High-Grade Lesions Samimi et al
5 Figure 4. Representative photomicrographs of Papanicolaou tests in women with various human papilloma virus (HPV) infection patterns. In this biopsy-confirmed, high-grade squamous intraepithelial lesions cohort lower-grade cytomorphology was often seen in mixed HPV-16/18 (A) and non- 16/18 hrhpv (B) infections, whereas high-grade cytologic features were more frequently associated with single-genotype infection with HPV-16 (C) or HPV-18 (D) (Papanicolaou, original magnification 3400 [A through D]). In the cohort with biopsy-confirmed HSILs, the women infected with non-16/18 hrhpv or mixed-hpv genotypes were significantly associated with deceptive lower-grade cytomorphology, compared with those infected with single HPV-16 or HPV-18 genotypes, contributing to falsenegative results or underdiagnosis on Pap tests. Clinically, HPV testing provides valuable information on HPV infection patterns, which may help in risk stratification. Vigilant surveillance and dynamic management protocols may be warranted for women infected with non-16/18 hrhpv or mixed-hpv genotypes. Information provided by HPV testing and genotyping likely is far greater than solely HPV-16/18. The overall infection pattern can be increasingly valuable in clinical risk management in light of the current challenges of HPV genotype shifting because of vaccination and human migration. Further studies of the mechanisms and the interactions among various HPV genotypes are needed to establish appropriate guidelines regarding followup and management of these patients. We thank Helen Chifotides, PhD, for editing of the manuscript. References 1. Gerberding, JL; Department of Health and Human Resources, eds. Centers for Disease Control(CDC): Prevention of Genital Human Papillomavirus Infection. Published January Accessed June Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1): Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353(20): Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92(6): Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14): Saslow D, Solomon D, Lawson HW, et al; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4): Coppleson LW, Brown B. Estimation of the screening error rate from the observed detection rates in repeated cervical cytology. Am J Obstet Gynecol. 1974;119(2): Moyer VA; US Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2013;158(11):852]. Ann Intern Med. 2012;156(12): Arch Pathol Lab Med Vol 142, March 2018 HPV Infections and High-Grade Lesions Samimi et al 351
6 9. Zhou H, Mody RR, Luna E, et al. Clinical performance of the Food and Drug Administration Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions. Cancer Cytopathol. 2016;124(5): American Society for Colposcopy and Cervical Pathology. Algorithms: Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Published August Accessed July Salazar KL, Zhou HS, Xu J, et al. Multiple human papilloma virus infections and their impact on the development of high-risk cervical lesions. Acta Cytol. 2015;59(5): Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991;265(4): Wright TC Jr., Stoler MH, Behrens CM, Sharma A, Sharma K, Apple R. Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial. Int J Cancer. 2014;134(8): Lyons Y, Kamat A, Zhou H, et al. Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL. Cancer Cytopathol. 2015;123(7): Zhou H, Mody D, Schwartz M, et al. Genotype-specific prevalence and distribution of human papillomavirus genotypes in underserved Latino women with abnormal Papanicolaou tests. J Am Soc Cytopathol. 2014;3(1): Chaturvedi AK, Katki HA, Hildesheim A, et al; CVT Group. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011;203(7): Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180(5): Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM; ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11): Silins I, Wang Z, Avall-Lundqvist E, et al. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol. 1999;80(pt 11): Sobota RS, Ramogola-Masire D, Williams SM, Zetola NM. Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer. Infect Agent Cancer. 2014;9:26. doi: / Luostarinen T, af Geijersstam V, Bjrge T, et al. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer. 1999;80(6): Heideman DA, Hesselink AT, Berkhof J, et al. Clinical validation of the Cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011; 49(11): Park Y, Lee E, Choi J, Jeong S, Kim HS. Comparison of the Abbott RealTime high-risk human papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol. 2012; 50(7): Submissions Now Accepted for the CAP18 Abstract Program Abstract and case study submissions to the College of American Pathologists (CAP) 2018 Abstract Program are now being accepted. Pathologists, laboratory professionals, and researchers in related fields are encouraged to submit original studies for possible poster presentation at the CAP18 meeting. Submissions will be accepted until 5 p.m. Central Friday, March 9, Accepted submissions will appear on the Archives of Pathology & Laboratory Medicine Web site as a Web-only supplement to the September 2018 issue. The CAP18 meeting will be held from October 20 to 24 in Chicago, Ill. Visit the CAP18 Web site ( and the Archives Web site (www. archivesofpathology.org) for additional abstract program information as it becomes available. 352 Arch Pathol Lab Med Vol 142, March 2018 HPV Infections and High-Grade Lesions Samimi et al
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationThe devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationHe Said, She Said: HPV and the FDA. Audrey P Garrett, MD, MPH June 6, 2014
He Said, She Said: HPV and the FDA Audrey P Garrett, MD, MPH June 6, 2014 Disclosure Speaker for Merck Gardasil Speaker for Hologic Thin Prep and Cervista Cervical Cancer Screening: 21 st century Dr. Papanicolaou
More informationThe ATHENA HPV study underrepresents other high-risk HPV genotypes when compared with a diverse New York City population
Accepted: 6 March 2017 DOI: 10.1111/cyt.12440 ORIGINAL ARTICLE The ATHENA HPV study underrepresents other high-risk HPV genotypes when compared with a diverse New York City population G. Ramos Rivera a
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationP16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future. Mark H Stoler, MD University of Virginia Health System, Charlottesville, VA,
More informationNILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA
NILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA Focused Rescreening Prior to Report Issuance, An Enhanced Quality Control Measure Karen Cormier, CT(ASCP), 1 Michael
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More informationHPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China
2436 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(13): 2436-2441. doi: 10.7150/jca.19421 HPV test results and histological follow-up results of patients with LSIL Cervical
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationAbnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology,
More informationCervical cancer prevention: Advances in primary screening and triage system
Cervical cancer prevention: Advances in primary screening and triage system Dr Farid Hadi Regional Medical and Scientific Affairs Roche Diagnostics Asia-Pacific, Singapore Cervical cancer is highly preventable
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationCan HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
More informationPrior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory
Prior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory Baowen Zheng, MD 1 ; Zaibo Li, MD, PhD 2 ; Christopher C. Griffith, MD, PhD
More informationGYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital
GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital and Bioreference Labs (Houston) Department of Pathology
More information(Pap) results, ie, abnormal squamous cells of undetermined significance (ASCUS). According to
The Role of Human Papillomavirus Type 16/18 Genotyping in Predicting High-Grade Cervical/Vaginal Intraepithelial Neoplasm in Women With Mildly Abnormal Papanicolaou Results Ming Guo, MD 1 ; Yun Gong, MD
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationHUMAN PAPILLOMAVIRUS TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationThe Biology of HPV Infection and Cervical Cancer
The Biology of HPV Infection and Cervical Cancer Kaitlin Sundling, M.D., Ph.D. Clinical Instructor Faculty Director, Cytotechnology Program Wisconsin State Laboratory of Hygiene and University of Wisconsin
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationCME/SAM. Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results
Anatomic Pathology / HPV-Negative ASC-H Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results David Cohen, MD, R. Marshall Austin, MD,
More informationCME/SAM. High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up
Anatomic Pathology / HPV Testing in Negative Papanicolaou Tests High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up Michael
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationCervical Cancer Screening
Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More information32 OBG Management May 2015 Vol. 27 No. 5 obgmanagement.com
The Advisory Committee on Immunization Practices recommends routine vaccination against HPV in 11- and 12-year-olds, although the age can range from 9 to 26 years (for those who have not been vaccinated
More informationEmerging Challenges in Primary Care. Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing
Emerging Challenges in Primary Care Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner
More informationOriginal Articles. Squamous Cell Carcinoma of the Cervix. A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice
Original Articles Squamous Cell Carcinoma of the Cervix A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice Ross A. Miller, MD; Lindsay L. Waters, MD; Dina R. Mody, MD; Kimberlee
More informationUpdate on HPV Testing. Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories
Update on HPV Testing Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories Disclosures In accordance with ACCME guidelines, any individual
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationBiomarkers and HPV testing: The future of cervical screening
THE FUTURE OF CERVICAL SCREENING Earn 3 CPD Points online Biomarkers and HPV testing: The future of cervical screening Professor John O Leary Associate Professor and Director of Pathology Coombe Women
More informationPAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim
More informationA Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,
Correlation Between Hybrid Capture II High-Risk Human Papillomavirus DNA Test Chemiluminescence Intensity From Cervical Samples With Follow-Up Histologic Results A Cytologic/Histologic Review of 367 Cases
More informationMolecular Triage: Partial and Extended Genotyping and More!
Molecular Triage: Partial and Extended Genotyping and More! Thomas C. Wright, Jr. MD Professor Emeritus Columbia University, New York Pathologist, Enzo Clinical Laboratories, Farmingdale, NY Disclosures
More informationComparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic biopsy
Iranian Journal of Reproductive Medicine Vol.5. No.3. pp:121-126, Summer 2007 Comparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic
More informationCytology Report Format
Squamous Precursor Lesions and Malignancies In Pap Test Dina R. Mody, MD, FCAP Director of Cytology The Methodist Hospital, Houston, TX Professor of Pathology and Laboratory Medicine Weill Medical College
More informationSouthern California CSU DNP Consortium
Southern California CSU DNP Consortium California State University, Fullerton California State University, Long Beach California State University, Los Angeles ESSENTIAL CHANGES TO THE MANAGEMENT OF ABNORMAL
More informationHuman Papillomavirus Testing Using Hybrid Capture II With SurePath Collection
468 Human Papillomavirus Testing Using Hybrid Capture II With SurePath Collection Initial Evaluation and Longitudinal Data Provide Clinical Validation for This Method Vincent Ko, MD Rosemary H. Tambouret,
More informationPushing the Boundaries of the Lab Diagnosis in Asia
Pushing the Boundaries of the Lab Diagnosis in Asia Diana Lim MBBS, FRCPA, FRCPath (UK) Senior Consultant National University Health System and National University of Singapore Department of Pathology
More informationOutcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure
The Korean Journal of Pathology 2012; 46: 359-364 ORIGINAL ARTICLE Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure Joon Seon Song Ilseon
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationCervical Cancer 4/27/2016
Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about
More informationAtypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More informationComparing Liquid-Based Cytology Methods in the Detection of Cervical Cancer: Perspectives from Dr. Ming Guo
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/advances-in-womens-health/comparing-liquid-based-cytology-methodsdetection-cervical-cancer-perspectives-dr-ming-guo/7469/
More informationVaginal Neoplasia-A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results
Vaginal Neoplasia-A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results Michelle J. Khan, MD, MPH Assistant Professor Department of Obstetrics and Gynecology
More informationCervical cancer screening in vaccinated population
Cervical cancer screening in vaccinated population Cytology and molecular testing Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol Oncol Izmir, November
More informationCervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients Richard Hopley, MD, Alexandra Gillespie, MD* Laboratory Medicine 47:1:52-56 CLINICAL HISTORY Patients:
More informationHuman papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Human papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands Mitchell S Wachtel 1,
More informationchapter 4. The effect of oncogenic HPV on transformation zone epithelium
chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006 Galen M. Eversole, MD; Ann T. Moriarty,
More informationWelcome. THE ROLE OF oncofish cervical ASSESSMENT OF CERVICAL DYSPLASIA. March 26, 2013
THE ROLE OF oncofish cervical IN THE ASSESSMENT OF CERVICAL DYSPLASIA The phone lines will open, 15 minutes prior to the start of the webinar. Toll Free: 1-800-867-0864. Entry Code: 83956484. You may download
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationDisclosures Teresa M Darragh, MD
Below the Belt: Screening for HPV-associated Cancers Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Disclosures Teresa M Darragh, MD Hologic: Research
More informationCytomorphologic Features According to HPV DNA Type in Histologically Proven Cases of the Uterine Cervix
The Korean Journal of Pathology 2011; 45: 612-620 http://dx.doi.org/10.4132/koreanjpathol.2011.45.6.612 Cytomorphologic Features According to HPV DNA Type in Histologically Proven Cases of the Uterine
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationDisclosures & images
Cervical Cancer Screening: New Approaches Levi S. Downs, Jr., MD Disclosures & images During the previous 12 months, I have been a consultant for and received honoraria from Merck. Images are attributed
More informationRisk : How does it define cervical cancer screening?
Risk : How does it define cervical cancer screening? Alan G. Waxman, MD, MPH Dept. of Obstetrics and Gynecology University of New Mexico The University of New Mexico Disclosures I have no commercial interests
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationMolecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution. Mark H. Stoler, MD PSC Symposium USCAP 2008
Molecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution Mark H. Stoler, MD PSC Symposium USCAP 2008 Objectives: This presentation will briefly review the currently
More informationWELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1
WELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1 HOW TO CITE THIS ARTICLE: G. J. Vani Padmaja. Well Woman Clinic-Screening Program for Cervical Carcinomas. Journal of Evolution
More informationClinical Relevance of HPV Genotyping. A New Dimension In Human Papillomavirus Testing. w w w. a u t o g e n o m i c s. c o m
Clinical Relevance of HPV Genotyping A New Dimension In Human Papillomavirus Testing Human Papillomavirus: Incidence HPV prevalence was 26.8% for women in US aged 14 59 yrs 1 20 million Americans are currently
More informationCervical Cancer Prevention in the 21 st Century Changing Paradigms
Cervical Cancer Prevention in the 21 st Century Changing Paradigms Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M.
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationThe LAST Guidelines in Clinical Practice. Implementing Recommendations for p16 Use
AJCP / Original Article The LAST Guidelines in Clinical Practice Implementing Recommendations for p16 Use Lani K. Clinton, MD, PhD, 1,2 Kyle Miyazaki, 1 Asia Ayabe, 1 James Davis, PhD, 2 Pamela Tauchi-Nishi,
More informationNo Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016
Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical Director, PPWI Medical College of Wisconsin May 6,
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationOver-diagnoses in Cytopathology: Is histology the gold standard?
Over-diagnoses in Cytopathology: Is histology the gold standard? Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M. Darragh,
More informationDetecting High-Grade Cervical Disease on ASC-H Cytology. Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing
Anatomic Pathology / BD ProEx C Use in ASC-H Cy t o l o g y Detecting High-Grade Cervical Disease on ASC-H Cytology Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing Momin T. Siddiqui, MD,
More informationNegative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
Anatomic Pathology / FALSE-NEGATIVE HISTOLOGIC FINDINGS Negative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
More informationPrevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea
RESEARCH COMMUNICATION Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea Kidong Kim 1, Jin Ju Kim 2,3, Sun Mie
More informationHPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe. Mark H. Stoler, MD ASC Companion Meeting USCAP 2008
OBJECTIVES: HPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe Mark H. Stoler, MD ASC Companion Meeting USCAP 2008 1. Describe the concept of marker validation in the context of HPV tests. 2. Present
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationGynecologic Cytology-Histology Correlation Guideline
Gynecologic Cytology- Correlation Guideline George G. Birdsong, MD and Joe W. Walker, Jr., MS, SCT(ASCP) CM Clinical Practice Committee Dr. Birdsong and Mr. Walker are grateful for extensive input from
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6857 Cost-Effectiveness of Strategies for Detection CIN2+ in Women with ASC-US Pap Smears in Thailand RESEARCH ARTICLE Cost-Effectiveness Analysis of Different
More informationCan human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
J Gynecol Oncol. 2016 Nov;27(6):e56 pissn 2005-0380 eissn 2005-0399 Original Article Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification? Yeoun Eun
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More information9/19/17. Emerging Challenges in Primary Care: Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing. Faculty.
Emerging Challenges in Primary Care: 2017 Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause
More informationThe data from the ATHENA study and others bring this expectation and the appropriateness of the guidelines for women aged into question.
New data support HPV testing beginning at age 25 By Hope Cottrill, M.D. Recent findings from the ATHENA (Addressing the Need for Advanced HPV Diagnostics) study of cervical cancer screening revealed surprising
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationHuman Papillomaviruses: Biology and Laboratory Testing
For our patients and our population Human Papillomaviruses: Biology and Laboratory Testing Geoffrey Higgins Microbiology and Infectious Diseases For our patients and our population HPV Associated Cancers
More informationUtilization of the Biomarkers to Improve Cervical Cancer Screening
Utilization of the Biomarkers to Improve Cervical Cancer Screening Elena BERNAD Victor Babes University of Medicine and Pharmacy Timisoara, Romania Cervical cancer is at the second most common cancer in
More informationOctober 9, Dear Ms. Chowdhury:
October 9, 2017 Joya Chowdhury, MPH Senior Coordinator, USPSTF Department of Health and Human Services Agency for Healthcare Research and Quality Center for Evidence and Practice Improvement Room 06E65A
More informationEvidence-based treatment of a positive HPV DNA test. Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR
Evidence-based treatment of a positive HPV DNA test Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR HPV DNA testing Indications 1. Triage after cytology with ASCUS/LSIL
More informationHPV Molecular Diagnostics and Cervical Cytology. Philip E. Castle, PhD, MPH American Society for Clinical Pathology (ASCP) March 15, 2012
HPV Molecular Diagnostics and Cervical Cytology Philip E. Castle, PhD, MPH American Society for Clinical Pathology (ASCP) March 15, 2012 Disclosures & Disclaimers I serve on a Merck Data and Safety Monitoring
More informationPhilip E. Castle, Diane Solomon, Mark Schiffman, Cosette M. Wheeler for the ALTS Group
ARTICLEARTICLESHuman Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities Philip E. Castle, Diane Solomon, Mark Schiffman,
More informationHuman Papillomavirus Genotypes and the Cumulative 2-Year Risk of Cervical Precancer
MAJOR ARTICLE Human Papillomavirus Genotypes and the Cumulative 2-Year Risk of Cervical Precancer Cosette M. Wheeler, 1,2 William C. Hunt, 1 Mark Schiffman, 3 and Philip E. Castle, 3 for the Atypical Squamous
More information